GlassScriptPhysician profile
Rachel Dell
NPI 1457004624
$7,403.56
in general payments reported to CMS, 2019-2025
29 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4,078 · 2024: $3,220 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,391.41 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,339.65 | 2023-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $902.66 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $856.80 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $810.63 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $748.93 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $675.04 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $512.68 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $321.52 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $198.79 | 2023-2024 | Fanapt, Hetlioz |
| Novo Nordisk INC | $115.42 | 2023 | Wegovy |
| Neos Therapeutics, LP | $111.11 | 2023-2024 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $91.46 | 2023-2024 | Austedo Xr, Austedo |
| Noven Therapeutics, LLC | $82.57 | 2023-2024 | Xelstrym, Secuado |
| Cerapedics INC. | $82.10 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Idorsia Pharmaceuticals US INC | $82.05 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medacta USA, INC. | $81.78 | 2024 | |
| Tris Pharma INC | $75.40 | 2023-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $56.76 | 2023-2024 | Jornay Pm |
| Corium, LLC | $46.17 | 2023 | Azstarys |
| Bausch Health US, LLC | $40.75 | 2023-2024 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $34.20 | 2023 | Trintellix |
| Indivior INC. | $21.88 | 2023 | Sublocade |
| Owp Pharmaceuticals, INC. | $21.21 | 2023 | Lamotrigine, Subvenite |
| Lundbeck LLC | $20.49 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $18.77 | 2023 | Belsomra |
| Almatica Pharma LLC | $17.64 | 2024 | Loreev Xr |
| Biogen, INC. | $16.06 | 2024 | |
| Vertical Pharmaceuticals, LLC | $14.17 | 2024 | Relexxii |
| Janssen Scientific Affairs, LLC | $6.87 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Dell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.